Japan University News

26 June 2021 03:30

World’s First! Predicting the effectiveness of Immune Checkpoint Inhibitor. Expected to establish a personalized medical therapy for liver cancer -- Kindai University

- Predicted effectiveness of immune checkpoint inhibitors (ICIs) using a scoring system related to anti-cancer immune conditions

16 February 2021 12:12

Elucidation of the role of "Stress Granules" that can be therapeutic targets for cancer and ALS -- Kindai University

- Discovered for the first time in the world that Stress Granules (SGs) have the role of a "safety brake" that regulates signaling pathways that control cell proliferation, such as Protein Kinase C (PKC) and Mitogen-Activated Protein Kinase (MAPK). - SGs have the function of preventing excessive activation of MAPK by incorporating PKC.

1 February 2021 00:28

Mechanism of the selective induction of cancer cell-specific cell death by ACA-28 - Kindai University

- Elucidation of the mechanism of the compound "ACA-28" that selectively induces cell death in cancer cells - ACA-28 induces cell death of cancer cells and inhibits the growth by destroying tumor suppressor factors. - Expectations for the development of anticancer drugs with less side effects that target brakes instead of accelerators for cancer cells

Shows reduction, or enlargement, of tumor by patient. The bars heading downwards on the graph show patients with reductions, those heading upwards show enlargement.

11 June 2020 08:53

Efficacy of Opdivo (Nivolumab) in Cancer of Unknown Primary Cases Confirmed - Kindai University

- Efficacy of molecular target drug Nivolumab verified in investigator-initiated clinical trial for use with CUP by hospital team from Kindai University’s Faculty of Medicine - Reductions by more than half in tumor size in over 20% of CUP patients observed - Nivolumab expected to become standard treatment for CUP cases with no standard treatment

1 November 2019 05:00

Preclinical Stage Verification for Combined Use of a Drug Under Development with an Existing Drug to Stimulate the Immune System to Attack Cancer Cells - Kindai University

The research team from Kindai University's Faculty of Medicine, in cooperation with DAIICHI SANKYO COMPANY, LIMITED, have verified at the preclinical stage that using the currently under-development anti-cancer drug, U3-1402*1, in combination with immune checkpoint inhibitors*2 has the potential to be an effective treatment.

5 August 2019 02:00

Ground Breaking Development of World’s First CurativeTreatment of Intractable Hepatocellular Carcinoma Path to Establishment of Standard Treatment of Hepatocellular Carcinoma - Kindai University

Senior Administrator Masatoshi Kudo of Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology, with his research group has invented a new method (LEN-TACE) of treating patients with intractable multinodular or large liver cancers, particularly those with near advanced liver cancer.

Categories: cancer treatment